Streamlined customer solutions help the continuity of your vaccine practice

Convenient single-dose prefilled Tip-Lok syringe that doesn't require reconstitution and is color-coded to help with quick and easy identification.

Pediarix package
  • Immunization with PEDIARIX consists of 3 doses of 0.5 mL each by intramuscular injection at 2, 4, and 6 months of age (at intervals of 6 to 8 weeks, preferably 8 weeks). The first dose may be given as early as 6 weeks of age1
  • The preferred administration site is the anterolateral aspect of the thigh for children younger than 1 year. In older children, the deltoid muscle is usually large enough for an intramuscular injection1
  • The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk. Gluteal injections may result in suboptimal hepatitis B immune response1
  • Do not administer this product intravenously, intradermally, or subcutaneously1

See more about PEDIARIX dosing, administration, and implementation in the Nurses’ Guide video

  • Video transcript

    FOOTER TEXT ONSCREEN (for entire video):

    Please see Important Safety Information in this video and full Prescribing Information available at

    DR. LEN FRIEDLAND (All audio is spoken by Dr. Friedland):

    A Guide to the Administration of PEDIARIX for Nurses.

    Hi. My name is Len Friedland, and I’m the Vice President for Scientific Affairs and Public Health for GSK Vaccines. I’m a practicing pediatrician, fellowship trained in pediatric emergency medicine and a vaccine research scientist. Welcome to the eLecture series for PEDIARIX.

    This series of videos will explore the clinical, financial, and organizational benefits of using PEDIARIX and the other GSK DTaP-containing vaccines for your appropriate patients.

    Some of these attributes include supply reliability, schedule flexibility, the efficacy of PEDIARIX and its safety profile, and customer solutions, including cost-savings programs.

    In this video, we’ll cover dosing, administration, and storage, as well as barcodes and CPT codes to help you better manage your PEDIARIX supply and your immunization schedule.

    First, let’s take a look at the Indication for PEDIARIX.

    PEDIARIX is indicated for active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. PEDIARIX is approved for use as a 3-dose series in infants born of hepatitis B surface antigen-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).

    We know your practice gets busy, and maintaining the vaccination scheduling for your pediatric patients is a top priority. GSK is here to provide solutions to help maintain the continuity of your well-established primary series DTaP immunization schedule.

    At GSK, we also understand how important it is to continue your DTaP immunization routine without interruption. As the cornerstone of GSK’s DTaP-containing vaccine portfolio since 2002, PEDIARIX is here to help maintain the continuity of your primary series DTaP immunization schedule.

    PEDIARIX can be administered as early as 6 weeks of age, with the last dose given prior to the patient’s 7th birthday. For the primary vaccination series, PEDIARIX should be administered as an intramuscular injection at 2, 4, and 6 months of age. These three doses of PEDIARIX make up the primary immunization course for diphtheria, tetanus, pertussis, and poliomyelitis, and completes the course of vaccination against hepatitis B.

    PEDIARIX is dosed at intervals of 6 to 8 weeks, preferably 8 weeks. Data are not available on the safety and effectiveness of using PEDIARIX following one or more doses of a DTaP vaccine from a different manufacturer.

    PEDIARIX comes in a convenient 0.5-milliliter color-coded, single dose prefilled syringe. To help you reduce the steps in the administration process, the syringe is prefilled with a single-unit dose, and is color coded to help with identification. Please be aware that the tip caps of the prefilled syringes of PEDIARIX contain natural rubber latex and may cause allergic reactions.

    To further help save you time and manage your vaccine supply, PEDIARIX has 2-D bar codes that contain the National Drug Code (or, NDC) number, lot number, and expiration date.

    With this additional information, you can more easily update your inventory management system, patient records, and vaccination reports through any compatible Electronic Medical Record or Electronic Health Record.

    For your convenience, all the information you need for charting is found on the carton, including the lot number, expiration date, UPC and 2-D bar codes, and the numbers for both the syringe and the outer carton. The CPT code for PEDIARIX is 90723.

    GSK wants to help simplify all aspects of the vaccination process for your practice, which is why we’ve designed our vaccine packaging with you in mind. Now that we’ve talked about the packaging, let’s go over the administration process for PEDIARIX.

    Shake PEDIARIX vigorously to obtain a homogenous, turbid, white suspension. Once mixed, attach a sterile needle to the syringe and administer the dose of PEDIARIX intramuscularly.

    For children younger than 1 year of age, the preferred administration site is the anterolateral aspect of the thigh. In older children, the deltoid muscle is usually large enough for an intramuscular injection. PEDIARIX should not be injected in the gluteal area or in areas where there may be a major nerve.

    Do not administer PEDIARIX intravenously, intradermally, or subcutaneously.

    When storing your PEDIARIX supply, be sure to refrigerate between 2 and 8 degrees Celsius, that is, between 36 and 46 degrees Fahrenheit. If the vaccine has been frozen, do not use it, and be sure to dispose of it properly.

    Beyond supply, PEDIARIX supports your practice in other practical ways, with cost-savings programs such as optimized group pricing and multiple contract options. Contact your GSK Representative to learn more.

    We hope this video provided you with a better understanding of the dosing, administration, packaging, and storage of PEDIARIX.

    Thank you for partnering with GSK and PEDIARIX. We look forward to supplying the vaccines you need to help your patients and your practice.

    Keep your DTaP immunization routine running smoothly. Order PEDIARIX today by calling 1-866-475-8222, by visiting, or by contacting your GSK Sales Representative.

    Thank you for watching this video. For more information about PEDIARIX, please see the Important Safety Information and full Prescribing Information at


    Continue your DTaP immunization routine without interruption with PEDIARIX.

    Order PEDIARIX today: Call 1-866-475-8222. Visit or contact your GSK Sales Representative.

    Schedule a GSK Vaccine Business Review today to find out more about our Premium Partner program. For more information about PEDIARIX, please see the Important Safety Information in this video and full Prescribing Information available at

    You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit to file a report or call 1-800-822-7967.


    Important Safety Information for PEDIARIX.

    Contraindications for PEDIARIX are: severe allergic reaction (for example, anaphylaxis) after a previous dose of any diphtheria  toxoid-, tetanus toxoid-, pertussis-, hepatitis B-, or poliovirus-containing vaccine, or to any component of PEDIARIX; encephalopathy within 7 days of administration of a previous pertussis-containing vaccine; progressive neurologic disorders.

    In clinical trials, PEDIARIX was associated with higher rates of fever relative to separately administered vaccines.

    The decision to give PEDIARIX should be based on potential benefits and risks if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, or if adverse events (such as, temperature ≥105oF, collapse or shock-like state, persistent, inconsolable crying lasting ≥3 hours, occurring within 48 hours after vaccination; seizures within 3 days after vaccination) have occurred after receipt of a pertussis-containing vaccine.

    The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions.

    Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.

    For children at higher risk for seizures, an antipyretic may be administered at the time of vaccination with PEDIARIX.

    Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination with PEDIARIX should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination.

    In clinical trials, common adverse reactions in infants receiving PEDIARIX included injection-site reactions (pain, redness, and swelling), fever, drowsiness, irritability/fussiness, and loss of appetite.

    Vaccination with PEDIARIX may not result in protection in all vaccine recipients.


    Trademarks are property of their respective owners. ©2021 GSK or licensor. PDRVID200001 February 2021. Produced in USA.